Real-World Evidence (RWE) Oncology Solutions Market Size, Share & Trends Analysis by Component (Datasets, Consulting Services), Application, End User, and Geography - Global Opportunity Analysis and Industry Forecast (2026-2036)

List of Tables

Real-World Evidence (RWE) Oncology Solutions Market Size, Share & Trends Analysis by Component, Application, and End User- Global Opportunity Analysis and Industry Forecast (2026-2036)

According to the research report titled, 'Real-World Evidence (RWE) Oncology Solutions Market Size, Share & Trends Analysis by Component (Datasets, Consulting Services), Application (Drug Development & Approvals, Market Access & Reimbursement/Coverage Decisions, Medical Device Development & Approvals, Post-Market Surveillance), End User (Pharmaceutical, Biotechnology & Medical Device Companies; Healthcare Payers; Healthcare Providers), and Geography - Global Opportunity Analysis and Industry Forecast (2026-2036)' the global real-world evidence (RWE) oncology solutions market was valued at USD 974.1 million in 2026. This market is expected to reach USD 3,088.1 million by 2036, growing at a CAGR of 12.2% during the forecast period 2026 to 2036. The report provides an in-depth analysis of the global RWE oncology solutions market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036.

Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of this market is primarily driven by the increasing demand for robust real-world data to support oncology drug development and regulatory decision-making, the growing complexity and cost of oncology drug development accelerating reliance on RWE for external control arms and hybrid trial designs, the shift toward value-based healthcare encouraging payers and health technology assessment bodies to rely on real-world evidence for reimbursement and coverage decisions, and the rising global cancer burden reinforcing demand for scalable evidence-generation infrastructure. Moreover, expanding regulatory acceptance of RWE by agencies including the U.S. FDA and the EMA, rapid advancements in artificial intelligence and machine learning enabling more precise patient stratification and biomarker discovery, and the growing adoption of cloud-based RWE platforms supporting real-time integration of genomic and molecular data are expected to support the market's growth. However, concerns related to patient data privacy and security, lack of standardization in data collection practices, high implementation and maintenance costs, and limited interoperability between healthcare systems across different regions may restrain market growth.

The key players operating in the global RWE oncology solutions market are IQVIA Holdings Inc. (U.S.), Flatiron Health Inc. (U.S.), Tempus Labs Inc. (U.S.), ICON plc (Ireland), Parexel International Corporation (U.S.), Syneos Health Inc. (U.S.), Oracle Corporation (U.S.), Veracyte Inc. (U.S.), SAS Institute Inc. (U.S.), IBM Corporation (U.S.), Cognizant Technology Solutions Corporation (U.S.), UnitedHealth Group Incorporated (U.S.), Anthem Inc. (U.S.), Clinigen Group plc (U.K.), and PerkinElmer Inc. (U.S.), among others.

The global RWE oncology solutions market is segmented by component (datasets and consulting services), application (drug development & approvals, market access & reimbursement/coverage decisions, medical device development & approvals, post-market surveillance, and other applications), end user (pharmaceutical, biotechnology & medical device companies; healthcare payers; healthcare providers; and other end users), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on component, the datasets segment is expected to account for the largest share of the global RWE oncology solutions market in 2026. The segment dominates the global RWE oncology solutions market, primarily attributed to the exponential growth of medical data generated by hospitals, health systems, and cancer registries, the increasing dependence of outcome-based oncology studies on comprehensive real-world data, and the rising demand for drug safety and effectiveness information among healthcare payers, providers, and regulatory bodies. Oncology-specific datasets encompassing electronic health records, claims data, pathology reports, genomic sequencing results, and treatment outcome records provide the foundational evidence base required across all stages of cancer drug development and post-approval lifecycle management. The growing shift from volume-based to value-based care has significantly increased reliance on cancer registry data, EHR and EMR systems, and mobile health data, resulting in the generation of substantial medical data volumes that are directly applicable to RWE generation in oncology. The increasing availability of de-identified, research-grade oncology datasets from platforms such as Flatiron Health's EHR network and IQVIA's E360 platform is further expanding the accessibility and commercial value of oncology-specific data assets for pharmaceutical sponsors, regulators, and health technology assessment agencies.

The consulting services segment is also witnessing steady growth during the forecast period, driven by the increasing complexity of RWE study design and execution, the need for specialized regulatory expertise in preparing RWE submissions, and growing demand for health economics and outcomes research (HEOR) support among pharmaceutical and medical device companies seeking market access and reimbursement for novel oncology therapies.

Based on application, the market access & reimbursement/coverage decisions segment is expected to account for the largest share of the global RWE oncology solutions market in 2026. The segment holds the largest application share, primarily attributed to the increasing pressure on healthcare payers to demonstrate value for high-cost oncology therapies, the growing adoption of value-based contracting models, and the expanding role of health technology assessment bodies in coverage determinations across major markets. Oncology therapies frequently carry among the highest price tags in the pharmaceutical landscape, and payers in Europe, North America, and increasingly in Asia Pacific are requiring robust real-world evidence on clinical effectiveness, comparative outcomes, and economic impact as conditions for formulary inclusion and reimbursement approval. Health technology assessment agencies including NICE in the U.K., G-BA in Germany, and HAS in France are progressively incorporating real-world data requirements into their appraisal frameworks, reinforcing the strategic importance of RWE for oncology market access teams at pharmaceutical and biotechnology companies. The growing adoption of outcomes-based and risk-sharing agreements between manufacturers and payers further intensifies reliance on RWE for ongoing performance monitoring and contract compliance.

The drug development & approvals segment is also a major contributor, driven by pharmaceutical companies incorporating RWE alongside randomized controlled trials to optimize clinical trial design, accelerate regulatory approvals, and support label expansions for oncology indications. Post-market surveillance is witnessing steady growth, fueled by expanding mandatory pharmacovigilance obligations and voluntary long-term safety monitoring commitments from oncology sponsors.

Based on end user, the pharmaceutical, biotechnology & medical device companies segment is expected to account for the largest share of the global RWE oncology solutions market in 2026. The segment dominates the global RWE oncology solutions market, driven by the increasing importance of RWE studies across the full oncology drug development lifecycle and the growing need to assess drug performance in real-world clinical settings beyond the controlled conditions of randomized trials. Pharmaceutical and biotechnology companies are the primary buyers of oncology RWE datasets, analytics platforms, and consulting services, leveraging these capabilities for clinical trial optimization, regulatory submission support, label expansions, comparative effectiveness research, and commercial market access strategies. The growing pipeline of targeted oncology therapies, immune-oncology agents, and advanced cell and gene therapies, many of which target small and biomarker-defined patient populations where conventional trial designs are logistically or ethically challenging, is intensifying the strategic importance of RWE for demonstrating therapeutic value to regulators and payers alike. Medical device companies are also increasingly utilizing RWE to support pre-market approval submissions and post-market performance evaluations for oncology-related diagnostic and therapeutic devices.

Healthcare payers are the second-largest end-user segment, leveraging RWE to evaluate the real-world cost-effectiveness of oncology treatments, design outcomes-based reimbursement contracts, and develop evidence-based formulary management policies. Healthcare providers, including academic cancer centers, comprehensive cancer hospitals, and oncology specialty practices, also represent a growing end-user base for RWE solutions, using evidence generated from their own patient populations to optimize clinical pathways, benchmark treatment outcomes, and participate in collaborative multi-center oncology research networks.

A thorough geographic analysis of the industry gives detailed insights into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to account for the largest share of the global RWE oncology solutions market in 2026. North America's dominant position is primarily attributed to the rising burden of cancer in the region, the well-established shift toward value-based care models, the availability of robust and comprehensive electronic oncology datasets, a highly developed healthcare industry infrastructure, and the implementation of supportive regulatory frameworks including the 21st Century Cures Act and the U.S. FDA's Real-World Evidence Framework. The U.S. FDA's progressive expansion of pathways for incorporating RWE into regulatory submissions, including approvals for new indications and post-approval label changes, has provided clear institutional encouragement for investment in RWE capabilities by pharmaceutical sponsors and solution providers alike. The region hosts the world's highest concentration of RWE solution providers, oncology-focused analytics companies, academic cancer research centers, and clinical research organizations with specialized RWE capabilities, creating a dense and highly competitive market ecosystem that continuously advances the quality and analytical sophistication of oncology real-world evidence.

Asia Pacific is expected to witness the highest growth rate during the forecast period, driven by the rapid expansion of healthcare digitization infrastructure across China, Japan, South Korea, India, and Taiwan; the increasing and growing cancer burden across the region; and growing government-led investment in health data infrastructure and precision medicine programs. The expanding pharmaceutical market and rapidly growing clinical trial landscape in Asia Pacific are also generating strong demand for RWE solutions to support regulatory submissions and market access strategies in both regional and global markets.

Europe represents the second-largest regional market, supported by landmark regulatory and data-sharing initiatives including the European Health Data Space (EHDS) and the EMA's DARWIN EU network, which have launched over 100 real-world data studies including targeted oncology research. The strong institutional push for evidence-based coverage decisions by health technology assessment bodies across EU member states continues to drive demand for high-quality oncology RWE solutions.

Key Questions Answered in the Report-

What is the size of the global RWE oncology solutions market, and at what CAGR is this market projected to grow during 2026-2036?
What are the historical market sizes and growth rates of the global RWE oncology solutions market?
What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
Which segments in terms of component, application, and end user are expected to create major traction for the manufacturers in this market?
Which component segment is expected to hold the major share of the global RWE oncology solutions market in 2026, and what factors underpin its dominance?
How are advancements in AI, machine learning, and data analytics transforming real-world evidence generation in oncology?
What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for players operating in the global RWE oncology solutions market?
Who are the major players in the global RWE oncology solutions market? What are their specific product/service offerings and competitive strategies?
What are the recent strategic developments in the global RWE oncology solutions market? What are the impacts of these developments on the market?

Scope of the Report:

RWE Oncology Solutions Market Assessment - by Component

Datasets
- Electronic Health Records (EHR/EMR) Data
- Claims Data
- Cancer Registry Data
- Genomic & Molecular Data
- Patient-Reported Outcome Data
- Other Datasets
Consulting Services
- Study Design & Protocol Development
- Regulatory Consulting & Submission Support
- Health Economics & Outcomes Research (HEOR)
- Data Analytics & Statistical Services

RWE Oncology Solutions Market Assessment - by Application

Drug Development & Approvals
Market Access & Reimbursement/Coverage Decisions
Medical Device Development & Approvals
Post-Market Surveillance
Other Applications

RWE Oncology Solutions Market Assessment - by End User

Pharmaceutical, Biotechnology & Medical Device Companies
Healthcare Payers
Healthcare Providers
Other End Users

RWE Oncology Solutions Market Assessment - by Geography

North America
- U.S.
- Canada
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- South Korea
- India
- Taiwan
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa

Product Code: MRHC - 104590

Table of Contents

1. Introduction

1.1. Market DefInition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations

2. Research Methodology

2.1. Research Approach
2.2. Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research
2.3. Market Assessment
- 2.3.1. Market Size Estimation
- 2.3.2. Bottom-Up Approach
- 2.3.3. Top-Down Approach
- 2.3.4. Growth Forecast
2.4. Assumptions For The Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Drivers
- 4.2.1. GrowIng Demand For Real-World Evidence In Drug Development
- 4.2.2. IncreasIng Focus On Value-Based Healthcare
- 4.2.3. RisIng Cancer Incidence and Prevalence Globally
- 4.2.4. Regulatory Support For Rwe In Healthcare Decision-MakIng
- 4.2.5. Advancements In Data Analytics and Ai Technologies
4.3. RestraInts
- 4.3.1. Data Privacy and Security Concerns
- 4.3.2. Lack of Standardization In Data Collection
- 4.3.3. High Implementation and MaIntenance Costs
- 4.3.4. Limited Interoperability Between Healthcare Systems
4.4. Opportunities
- 4.4.1. Expansion In EmergIng Markets
- 4.4.2. Integration With Precision MedicIne Initiatives
- 4.4.3. Development of AI-Powered Analytics Solutions
- 4.4.4. Partnerships Between Healthcare Stakeholders
4.5. Trends
- 4.5.1. Shift Towards Patient-Centric Healthcare Models
- 4.5.2. Adoption of Cloud-Based Rwe Platforms
- 4.5.3. Integration of Genomic and Molecular Data
- 4.5.4. Real-Time Data Collection and Analysis
4.6. Challenges
- 4.6.1. Regulatory Compliance Across Different Regions
- 4.6.2. Data Quality and Completeness Issues
- 4.6.3. Integration of Disparate Data Sources
4.7. Porter's Five Forces Analysis
- 4.7.1. BargaInIng Power of Suppliers
- 4.7.2. BargaInIng Power of Buyers
- 4.7.3. Threat of Substitutes
- 4.7.4. Threat of New Entrants
- 4.7.5. Degree of Competition

5. Regulatory Analysis

5.1. Introduction
5.2. North America
5.3. Europe
5.4. Asia-Pacific
5.5. LatIn America
5.6. Middle East & Africa

6. PricIng Models (Emr/Genomic/Integrated Datasets)

6.1. Introduction
6.2. Pay Per Patient Record (Volume-Based PricIng)
6.3. Pay Per Usage (Value-Based PricIng)
6.4. Annual Subscription
6.5. Tiered PricIng Models
6.6. Custom Enterprise PricIng

7. Global Rwe Oncology Solutions Market, By Component

7.1. Overview
7.2. Datasets
- 7.2.1. Disparate Datasets
  - 7.2.1.1. EMR/EHR/ClInical Data
  - 7.2.1.2. Claims & BillIng Data
  - 7.2.1.3. Pharmacy Data
  - 7.2.1.4. Cancer Registries
  - 7.2.1.5. Other Disparate Datasets
- 7.2.2. Integrated Datasets
7.3. ConsultIng Services

8. Global Rwe Oncology Solutions Market, By Application

8.1. Overview
8.2. Drug Development & Approvals
8.3. Market Access & Reimbursement/Coverage Decisions
8.4. Medical Device Development & Approvals
8.5. Post-Market Surveillance
8.6. Other Applications

9. Global Rwe Oncology Solutions Market, By End User

9.1. Overview
9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
9.3. Healthcare Payers
9.4. Healthcare Providers
9.5. Other End Users

10. Rwe Oncology Solutions Market, By Geography

10.1. Overview
10.2. North America
- 10.2.1. U.S.
- 10.2.2. Canada
10.3. Europe
- 10.3.1. U.K.
- 10.3.2. Germany
- 10.3.3. France
- 10.3.4. Italy
- 10.3.5. SpaIn
- 10.3.6. Rest of Europe
10.4. Asia-Pacific
- 10.4.1. Japan
- 10.4.2. ChIna
- 10.4.3. India
- 10.4.4. South Korea
- 10.4.5. Taiwan
- 10.4.6. SIngapore
- 10.4.7. Australia
- 10.4.8. Rest of Asia-Pacific
10.5. LatIn America
- 10.5.1. Brazil
- 10.5.2. Mexico
- 10.5.3. Rest of LatIn America
10.6. Middle East & Africa
- 10.6.1. Uae
- 10.6.2. Saudi Arabia
- 10.6.3. South Africa
- 10.6.4. Rest of Mea

11. Competitive Landscape

11.1. Introduction
11.2. Competitive Dashboard
- 11.2.1. Industry Leaders
- 11.2.2. Market Differentiators
- 11.2.3. Vanguards
- 11.2.4. EmergIng Companies
11.3. Market Share/Position Analysis

12. Company Profiles

12.1. Iqvia HoldIngs Inc
- 12.1.1. Company Overview
- 12.1.2. FInancial Overview
- 12.1.3. Product Portfolio
- 12.1.4. Strategic Developments
- 12.1.5. Swot Analysis
12.2. Veracyte, Inc
- 12.2.1. Company Overview
- 12.2.2. FInancial Overview
- 12.2.3. Product Portfolio
- 12.2.4. Strategic Developments
- 12.2.5. Swot Analysis
12.3. Flatiron Health, Inc
- 12.3.1. Company Overview
- 12.3.2. Product Portfolio
- 12.3.3. Strategic Developments
- 12.3.4. Swot Analysis
12.4. Ibm Corporation
- 12.4.1. Company Overview
- 12.4.2. FInancial Overview
- 12.4.3. Product Portfolio
- 12.4.4. Swot Analysis
12.5. Oracle Corporation
- 12.5.1. Company Overview
- 12.5.2. FInancial Overview
- 12.5.3. Product Portfolio
- 12.5.4. Swot Analysis
12.6. Sas Institute Inc
- 12.6.1. Company Overview
- 12.6.2. Product Portfolio
- 12.6.3. Swot Analysis
12.7. Icon Plc
- 12.7.1. Company Overview
- 12.7.2. FInancial Overview
- 12.7.3. Product Portfolio
- 12.7.4. Swot Analysis
12.8. Parexel International Corporation
- 12.8.1. Company Overview
- 12.8.2. Product Portfolio
- 12.8.3. Swot Analysis
12.9. Syneos Health, Inc
- 12.9.1. Company Overview
- 12.9.2. Product Portfolio
- 12.9.3. Swot Analysis
12.10. Cognizant Technology Solutions Corporation
- 12.10.1. Company Overview
- 12.10.2. FInancial Overview
- 12.10.3. Product Portfolio
- 12.10.4. Swot Analysis
12.11. Unitedhealth Group Incorporated (Optum)
- 12.11.1. Company Overview
- 12.11.2. FInancial Overview
- 12.11.3. Product Portfolio
- 12.11.4. Swot Analysis
12.12. Anthem, Inc
- 12.12.1. Company Overview
- 12.12.2. FInancial Overview
- 12.12.3. Product Portfolio
- 12.12.4. Swot Analysis
12.13. ClInigen Group Plc
- 12.13.1. Company Overview
- 12.13.2. Product Portfolio
- 12.13.3. Swot Analysis
12.14. PerkInelmer, Inc
- 12.14.1. Company Overview
- 12.14.2. Product Portfolio
- 12.14.3. Swot Analysis
12.15. Tempus Labs, Inc
- 12.15.1. Company Overview
- 12.15.2. FInancial Overview
- 12.15.3. Product Portfolio
- 12.15.4. Strategic Developments
- 12.15.5. Swot Analysis

13. Appendix

13.1. Available Customization
13.2. Related Reports